Transaction DateRecipientSharesTypePriceValue
6th November 2020Capital Management, Llc Aquilo5,000Open or private sale$13.77$68,873.50
5th November 2020Capital Management, Llc Aquilo96,600Open or private sale$13.98$1,350,332.76
4th November 2020Capital Management, Llc Aquilo72,500Open or private sale$14.26$1,033,741.25
23rd October 2020Ankit Mahadevia20Open or private sale$14.25$285.00
23rd October 2020Ankit Mahadevia20Exercise of derivative$5.90$118.00
14th October 2020Ankit Mahadevia105Open or private sale$14.25$1,496.25
14th October 2020Ankit Mahadevia105Exercise of derivative$5.90$619.50
13th October 2020Ankit Mahadevia14,367Exercise of derivative$5.90$84,765.30
13th October 2020Ankit Mahadevia14,367Open or private sale$14.28$205,212.48
8th September 2020Ankit Mahadevia774Exercise of derivative$5.90$4,566.60
Spero Therapeutics
Spero Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013.

Ticker: SPRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1701108
Employees: 57
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $65 M (119%)
Marketable Securities, Current: $6 M (-88%)
Assets, Current: $85 M (-10%)
Property, Plant and Equipment, Net: $2 M (-12%)
Other Assets, Noncurrent: $5 M (44%)
Assets: $98 M (-8%)
Accounts Payable, Current: $2 M (-62%)
Liabilities, Current: $19 M (-28%)
Liabilities: $24 M (-24%)
Common Stock, Value, Issued: $21 Th (10%)
Common Stock, Shares, Issued: $21 M (9%)
Additional Paid in Capital, Common Stock: $314 M (14%)
Retained Earnings (Accumulated Deficit): $240 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $15 Th (-6%)
Stockholders' Equity (Parent): $74 M (-1%)
Liabilities and Equity: $98 M (-8%)
Revenue: $51 Th (-76%)
Research and Development: $16 M (-56%)
General and Administrative Expenses: $5 M (-47%)
Operating Income/Loss: $18 M (-55%)
Other Income, net: $975 Th (81%)